24 studies found for:    S1007
Show Display Options
Rank Status Study
1 Recruiting Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Letrozole;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
2 Completed Study to Evaluate the Safety and Efficacy of S-297995 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain
Condition: Opioid Induced Bowel Dysfunction
Interventions: Drug: 0.1 mg of S-297995 or placebo;   Drug: 0.3 mg of S-297995 or placebo;   Drug: 1 mg of S-297995 or placebo;   Drug: 3 mg of S-297995 or placebo;   Drug: 0.03 mg of S-297995 or placebo;   Drug: 0.01 mg of S-297995 or placebo
3 Completed A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: continuous infusion of 5-fluorouracil;   Drug: combination of irinotecan and cisplatin;   Drug: oral administration of S-1
4 Recruiting S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: TAK-700;   Drug: Bicalutamide
5 Recruiting S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Condition: Kidney Cancer
Interventions: Drug: everolimus;   Other: placebo
6 Recruiting S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer
Condition: Bladder Cancer
Interventions: Procedure: therapeutic conventional surgery;   Procedure: therapeutic lymphadenectomy
7 Recruiting (C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: SAN-300;   Drug: Placebo
8 Active, not recruiting Sientra Post-Approval Study
Conditions: Breast Augmentation;   Breast Reconstruction;   Breast Revision
9 Completed
Has Results
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes
Condition: Stroke
Interventions: Drug: Aggrenox;   Drug: Clopidogrel placebo;   Drug: Micardis;   Drug: Aggrenox placebo;   Drug: Clopidogrel;   Drug: Micardis placebo
10 Completed
Has Results
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
Condition: Cardiovascular Diseases
Interventions: Drug: Telmisartan;   Drug: Combination of Telmisartan and Ramipril;   Drug: Ramipril
11 Completed Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects
Conditions: Acquired Bleeding Disorder;   Acquired Haemophilia;   Congenital Bleeding Disorder;   Congenital FVII Deficiency;   Glanzmann's Disease;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors;   Healthy
Intervention: Drug: activated recombinant human factor VII
12 Completed ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Condition: Psoriasis
Interventions: Drug: ACT-128800;   Drug: Placebo
13 Completed LAS41005 in Hyperkeratotic Actinic Keratosis
Condition: Hyperkeratotic Actinic Keratosis
Interventions: Procedure: Cryotherapy;   Drug: LAS41005
14 Completed Tolerability and Pharmacokinetics of Metformin and Metformin Extended Release (ER)
Condition: Healthy
Interventions: Drug: metformin ER;   Drug: metformin
15 Completed An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults
Conditions: Bacterial Infections;   Staphylococcal Vaccines;   Immunotherapy, Active;   Staphylococcal Skin Infections;   Staphylococcal Infections
Interventions: Biological: SA3Ag vaccine;   Procedure: Blood draw;   Procedure: Colonization swab samples;   Biological: SA3Ag followed by Placebo;   Biological: Placebo;   Biological: SA3Ag with no booster in stage 2;   Procedure: Placebo with no booster in stage 2
16 Terminated Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus
Condition: Subjective Tinnitus
Intervention: Drug: Neramexane mesylate
17 Completed
Has Results
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium;   Drug: placebo
18 Terminated A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR)
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Foster® 100/6 µg/unit dose;   Drug: Symbicort® Turbohaler® 200/6 μg/actuation
19 Recruiting Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy
Condition: Prostate Cancer
Interventions: Drug: endocrine therapy;   Procedure: radiotherapy
20 Recruiting Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma
Condition: Primary Central Nervious System Lymphoma
Interventions: Drug: TEDDI;   Biological: Rituximab;   Drug: Cytarabine

   Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results    Last Page
Indicates status has not been verified in more than two years